Table 3.
Measurements of muscle strength, VAS, and Lequesne index scores in the GEJ-treated group (n = 21) before and after 12 weeks of treatment.
| Variables | Pretreatment | Posttreatment | |||||
|---|---|---|---|---|---|---|---|
| Median | P 25 | P 75 | Median | P 25 | P 75 | P value | |
| Measurements of muscle strength | |||||||
| PeakTQ-ext-nondominant (Nm) | 38.80 | 18.20 | 45.90 | 52.10 | 37.90 | 65.30 | 0.007∗∗ |
| PeakTQ-ext-dominant (Nm) | 29.10 | 19.50 | 49.60 | 51.60 | 40.10 | 62.60 | 0.001∗∗ |
| PeakTQ-flex-nondominant(Nm) | 19.50 | 14.40 | 32.60 | 20.70 | 19.10 | 36.20 | 0.085 |
| PeakTQ-flex-dominant (Nm) | 18.80 | 15.70 | 33.20 | 30.80 | 21.70 | 36.70 | 0.092 |
| TQ/BW-ext-nondominant (ft·lb/lb) | 66.60 | 35.30 | 83.10 | 76.50 | 71.70 | 103.90 | 0.006∗∗ |
| TQ/BW-ext-dominant (ft·lb/lb) | 57.80 | 27.40 | 82.40 | 87.10 | 58.90 | 99.40 | 0.001∗∗ |
| TQ/BW-flex-nondominant (ft·lb/lb) | 33.00 | 24.40 | 51.20 | 39.70 | 31.40 | 55.80 | 0.092 |
| TQ/BW-flex-dominant (ft·lb/lb) | 37.30 | 24.20 | 53.80 | 47.50 | 38.20 | 58.60 | 0.076 |
| Measurements of visual analog pain scale score (VAS) | |||||||
| visual analog pain scale score | 2.00 | 0.00 | 3.00 | 0.00 | 0.00 | 2.00 | 0.005∗∗ |
| Measurements of Lequesne index score | |||||||
| Lequesne index score | 6.00 | 3.00 | 9.00 | 3.00 | 0.00 | 6.00 | 0.001∗∗ |
| (I) Pain or discomfort | 2.00 | 1.00 | 3.00 | 0.00 | 0.00 | 1.00 | 0.003∗∗ |
| (II) Maximum distance walked | 1.00 | 1.00 | 3.00 | 1.00 | 0.00 | 2.00 | 0.150 |
| (III) Activities of daily living | 2.00 | 1.00 | 5.00 | 1.00 | 0.00 | 3.00 | 0.032∗ |
Wilcoxon signed-rank test; ∗P < 0.05; ∗∗P < 0.01.